The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Ochre Bio Launches ‘Liver ICU’ in US to Evaluate Effects of RNA Therapies on Human Liver Performance

11 May 2022

Ochre plans to maintain hundreds of discarded donor livers outside the body, mimicking human physiological conditions, to test the efficacy of new RNA therapeutics. Research is expected to advance the understanding of liver biology, with the goal of improving liver transplant outcomes and discovering novel therapies for liver diseases. Ochre announces partnerships with OrganOx, leaders in the field of liver perfusion technology, as well as... Read more

OrganOx announces partnership with Ochre Bio

11 May 2022

OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that it has partnered with Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases. Under the terms of the partnership OrganOx will provide metra devices to Ochre Bio and its partners to evaluate the efficacy of novel RNA therapeutics using discarded donor livers perfused on the metra. Craig Marshall, OrganOx CEO, commented: “Thanks... Read more

OrthoSon completes £8.9m expanded Series A to accelerate back pain treatment’s progress to clinic

03 May 2022

OrthoSon completes £8.9m expanded Series A to accelerate back pain treatment’s progress to clinic Big Pi Ventures & Yonghua Capital are new international investors in expanded round Oxford, UK, May 3 2022 – OrthoSon, which is developing novel motion-restoring minimally invasive treatments for low back pain, is pleased to announce completion of a £8.9m Series A fund round to help prepare its product for Phase I trials in the US. New... Read more

OMass Therapeutics Raises $100m in Series B to Progress Drug Pipeline

28 Apr 2022

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises, and Oxford University also participating Investment will advance OMass’s portfolio of novel drugs against highly-validated, yet intractable or inadequately drugged, membrane- and... Read more

Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Office

05 Apr 2022

OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia’s drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific... Read more

News